Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ursodiol

FDA-approved product (capsule, oral), marketed as Actigall, Urso 250, Urso Forte and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ursodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Biliary liver cirrhosis
  • Primary biliary cirrhosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bile acids and derivatives
FDA pharmacologic class
Bile Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ursodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ursodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lithotripsy for the Treatment of Gallstones

    NCT00042549 · start 2002-05

    Registered record
    Registry ID
    NCT00042549
    Conditions
    Cholelithiasis
    Interventions
    Extracorporeal Shock Wave Lithotripsy; ursodiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2002-05
    Completion
    Not recorded
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholelithiasis
    InterventionExtracorporeal Shock Wave Lithotripsy; ursodiol
    PhasePhase 4
    Registry statusTerminated

  • Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy

    NCT01576458 · start 1998-01

    Registered record
    Registry ID
    NCT01576458
    Conditions
    Intrahepatic Cholestasis; Pregnancy
    Interventions
    ursodeoxycholic acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-01
    Completion
    1998-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholestasis; Pregnancy
    Interventionursodeoxycholic acid; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

    NCT00004441 · start 1997-09

    Registered record
    Registry ID
    NCT00004441
    Conditions
    Cystic Fibrosis
    Interventions
    tauroursodeoxycholic acid; ursodiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-09
    Completion
    2001-09
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventiontauroursodeoxycholic acid; ursodiol
    PhaseNot applicable
    Registry statusCompleted

  • Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis

    NCT00004784 · start 1994-01

    Registered record
    Registry ID
    NCT00004784
    Conditions
    Liver Cirrhosis, Biliary
    Interventions
    methotrexate; ursodiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-01
    Completion
    Not recorded
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis, Biliary
    Interventionmethotrexate; ursodiol
    PhasePhase 3
    Registry statusCompleted

  • Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody

    NCT01430429

    Registered record
    Registry ID
    NCT01430429
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    NI-0801
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionNI-0801
    PhasePhase 2
    Registry statusTerminated